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Edited by Varda RotterAbstract Human Topors, which was originally identiﬁed as cel-
lular binding partner of DNA topoisomerase I and of p53, has
recently been shown to function as an ubiquitin E3 ligase for
p53 in a manner dependent on its N 0-terminally located RING
ﬁnger. Here, we demonstrate that Topors also enhances the con-
jugation of the small ubiquitin-like modiﬁer 1 (SUMO-1) to p53
in vivo and in a reconstituted in vitro system. The Topors
SUMO-1 E3 ligase activity does not depend upon its RING ﬁn-
ger motif. In HeLa cells, Topors induced p53 sumoylation was
accompanied by an increase in endogenous p53 protein levels.
Furthermore, Topors enhances the sumoylation of a variety of
other, yet unidentiﬁed, cellular proteins.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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SUMO-1, the small ubiquitin-like modiﬁer 1, can be cova-
lently linked to a variety of cellular target proteins by an enzy-
matic machinery, which is very similar to the ubiquitin
conjugation system. After activation by the heterodimeric E1
enzyme Aos-1/Uba2 [1] and formation of a thioester with the
E2 conjugating enzyme UBC9 [2], SUMO-1 is attached to spe-
ciﬁc lysine residues within the target protein. Ubiquitin conju-
gating enzyme 9 (UBC9) physically interacts with many known
SUMO-1 substrates [3] and the E1 and E2 enzymes are suﬃ-
cient for the SUMO-1 modiﬁcation of a variety of these sub-
strates in reconstituted systems [3]. Furthermore, several
diﬀerent types of SUMO-1 E3 ligases, which stimulate the
SUMO-1 modiﬁcation of speciﬁc substrates, have been identi-
ﬁed recently. These include diﬀerent members of the protein
inhibitors of activated STAT (PIAS) protein family [4,5], the
nucleoporin RanBP2 [6] and the Polycomb Protein Pc2 [7].
In contrast to the PIAS proteins, which require a RING-like
motif for their ligase activity, the catalytic domains of the lat-
ter two proteins do not contain any RING related sequences.
Sumoylation has been implicated in various functions such
as regulation of the stability, the intracellular localization
and the transcriptional activity of the respective target proteinAbbreviations: SUMO, small ubiquitin-like modiﬁer; UBC9, ubiquitin
conjugating enzyme 9; GST, glutathione S-transferase; GFP, green
ﬂuorescent protein; YFP, yellow ﬂuorescent protein; PIAS, protein
inhibitors of activated STAT; HCMV, human cytomegalovirus
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modiﬁed by a single SUMO-1 moiety at lysine residue 386, it
was initially suggested that sumoylation moderately enhances
its transcriptional activity [9,10]. However, this issue remains
controversial, since no such functional eﬀects could be
observed in later studies [11].
Topors is a cellular RING ﬁnger protein that binds to
DNA topoisomerase I [12] and p53 [13]. It is located in nu-
clear speckles closely associated with the PML oncogenic
domains (PODs) [14,15]. While widely expressed in normal
human tissues, it exhibits strongly reduced expression levels
in colon adenocarcinomas and several colon cancer cell lines
[16]. Topors possesses RING ﬁnger dependent ubiquitin E3
ligase activity and is able to ubiquitinate p53 in vitro and
in vivo [17]. Recently, it was shown that the forced expres-
sion of the murine counterpart of Topors stabilizes p53 and
enhances its transcriptional activity [18]. In this study, we
examined a possible function of Topors as an SUMO-1 E3
ligase for p53 both in vivo and in a reconstituted in vitro
sumoylation system.2. Materials and methods
2.1. Plasmid construction
Plasmid pEYFP-SUMO-1, which expresses an yellow ﬂuorescent
protein (YFP)-tagged SUMO-1 protein, and most of the pCATCH-
Topors plasmids, which express various parts of the Topors open read-
ing frame fused to an N-terminal located Flag-tag epitop under control
of the human cytomegalovirus (HCMV) promoter, have already been
described [15]. In pCATCH-Topors-RD, the entire Topors RING ﬁn-
ger motif encompassing amino acids 103–141 was deleted through
PCR based mutagenesis. Plasmid pRC/CMV-p53 for eukaryotic
expression and in vitro transcription/translation of p53 was kindly pro-
vided by Haupt. The luciferase reporter gene construct PG13-Luc [19],
which contains 13 copies of the p53-binding consensus sequence, was
kindly provided by Vogelstein.
Plasmids pGEX-Topors(1-1045) encoding a glutathione S-transfer-
ase (GST)-Topors fusion protein was generated by subcloning the
EcoRI/NotI Topors fragments from pCATCH-Topors(1-1045) into
pGEX-4T1 (Amersham Pharmacia). For pGEX-Topors(268-644),
the XhoI/PstI Topors fragment from pCATCH-Topors(268-644) [15]
was subcloned into Bluescript SK2 (Stratagene), excised with XhoI
and NotI and ligated to XhoI/NotI digested vector pGEX-4T2 (Amer-
sham Pharmacia).
2.2. In vitro sumoylation assays
Puriﬁcation of GST fusion proteins from bacteria (BL21) was per-
formed essentially as described [20]. 35S-labelled p53 was obtained by
coupled in vitro transcription/translation (Promega) of pRC/CMV-
p53 in rabbit reticulocyte lysates with T7 RNA polymerase in the
presence of 35S-methionine. Two microlitres of the translation product
was incubated for 2 h at 30 C in a 20 ll reaction (50 mM Tris, pH 7.5,
5 mM MgCl2, 2 mM ATP) containing 2 lg SUMO-1(1-97) (Alexisblished by Elsevier B.V. All rights reserved.
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icals) and 40 ng UBC9 (Boston Biochem). Puriﬁed GST-Topors pro-
teins were added in a concentration range of 0.1–1.0 lg.
2.3. Cell culture, transient transfections, Western blotting and
transcription reporter assays
HeLa cells maintained in Dulbeccos modiﬁed Eagle Medium sup-
plemented with 10% fetal bovine serum were transfected with the indi-
cated plasmids by the calcium phosphate precipitate technique for 16 h
at 37 C and 5% CO2. After medium replacement, cells were incubated
for a further 24 h period. For immunoblot analysis, cells were directly
lysed in 200 ll of SDS sample buﬀer per 60 mm culture dish and
proteins were separated by SDS–PAGE. Immunodetections was per-
formed either with the monoclonal anti-p53 antibody DO-1 (Santa
Cruz), a monoclonal UBC9 antibody (Transduction Laboratories),
the monoclonal anti-Flag antibody M2 (Sigma) or a polyclonal anti-
green ﬂuorescent protein (GFP) antiserum from goat (Biotrend),
which is also reactive with the YFP protein (therefore, referred to as
anti-YFP in the following). For luciferase reporter assays, cells were
lysed in 400 ll of reporter lysis buﬀer and 50 ll of cell extract were ana-
lyzed with the Bright-Glo Luciferase Assay System (Promega) using a
Berthold Centro LB960 apparatus.
2.4. Immunoprecipitation analysis
Transfected cells in 100 mm diameter cell culture dishes were lysed
directly by the addition of 2 ml of RIPA buﬀer (50 mM Tris–HCl,
pH 8.0, 150 mM NaCl, 0.5% DOC, 0.1% SDS and 1% NP40) contain-
ing 10 mM iodoacetamide at 4 C for 10 min. Lysates were clariﬁed by
15 min centrifugation at 20800 · g and 4 C. The supernatant was
incubated with 5 lg of monoclonal p53 antibody Pab1801 (Santa
Cruz) coupled to agarose beads for 1 h at 4 C. Beads were washed 5
times with RIPA buﬀer containing 10 mM iodoacetamide. Immuno-
precipitated proteins were analyzed by Western blot using the anti-
YFP antiserum.3. Results and discussion
We have recently shown that Topors interacts with SUMO-1
and the corresponding conjugating E2 enzyme UBC9 and,
consequently, can be modiﬁed by several SUMO-1 residues
[15]. Furthermore, independent of its own SUMO-1 modiﬁca-
tion, Topors also induces the relocation of an exogenous
SUMO-1 protein into characteristic nuclear speckles [15]. This
ﬁnding prompted us to address the question whether Topors
might be involved in the sumoylation of other proteins. After
coexpression of an YFP-tagged SUMO-1 protein with increas-
ing amounts of a Flag-tagged full-length Topors protein in
HeLa cells, we observed a clear increase in the amount of
high-molecular weight forms of YFP-SUMO-1 (Fig. 1A).
Since the cells were directly lysed under denaturing conditions,
these high-molecular weight forms most probably present con-
jugates of YFP-SUMO-1 to other proteins. A similar increase
in the amount of conjugated YFP-SUMO-1 forms was seen
after cotransfection of a Topors protein with a deletion of
the complete RING ﬁnger motif (Fig. 1A, DRING). Both
the wild-type Topors protein and the DRING mutant can be
modiﬁed by multiple YFP-SUMO-1 moieties (Fig. 1C, lower
panel). Therefore, it may be argued that the high-molecular
weight forms of YFP-SUMO-1 exclusively reﬂect the modiﬁca-
tion of Topors itself. However, this argumentation cannot be
extended to the increase in the formation of conjugated
YFP-SUMO-1 observed after transfection of two Topors mu-
tants, which exclusively harbour sequences from the central
part of the Topors protein (Fig. 1B, Topors 437/574 and
437/555). Topors 437/574 is only weakly modiﬁed by one or
two YFP-SUMO-1 moieties with the conjugates migratingfar below the below the bulk of conjugates detected in the
YFP immunoblot and sumolyation of the Topors 437/555
mutant is barely detectable (Fig. 1D). These two mutants were
selected, because they have been shown to induce a similar
relocation of an exogenous SUMO-1 into the Topors nuclear
speckles as the full-length protein [15]. As opposed to these
two constructs, the Topors(491/574) mutant, which lacks the
SUMO-1 binding site [15], is not able to induce an increase
in the conjugated forms of YFP-SUMO-1 (Fig. 1B). These
results suggest that Topors, by virtue of its central SUMO-1
binding domain, can enhance the sumoylation of a variety of
cellular proteins. Such broad substrate speciﬁcity seems to be
a general hallmark of SUMO-1 ligases, since it was observed
for most SUMO-1 E3 enzymes characterized so far [21].
As p53 can bind to the central region of the Topors protein
[13,22], it represented one likely substrate for the Topors
SUMO-1 ligase activity. Therefore, we investigated the inﬂu-
ence of Topors on p53 sumoylation by cotransfection of a
p53 expression construct and the YFP-tagged SUMO-1 pro-
tein together with increasing amount of Topors expression
constructs. p53 Sumoylation was monitored by the appearance
of an additional anti-p53 reactive band of about 90 kDa
(Fig. 2A), whose identity as an YFP-SUMO-1 conjugated
form of p53 was conﬁrmed in immunoprecipitations
(Fig. 2C). The expression of either the wild-type Topors
protein or the RING ﬁnger deletion mutant at intermediate
concentrations led to an enhancement of p53 sumoylation
(Fig. 2A). In addition, a central Topors domain harbouring
at least Topors amino acids 437–555 enhanced p53 sumoyla-
tion at all concentrations tested (Fig. 2B). This eﬀect was not
due to an overall increase in the amount of p53. The reversal
of the stimulation of p53 sumoylation at high concentrations
of full-length Topors protein might be due to additional activ-
ities associated with the full-length protein. Topors has been
shown to possess a RING ﬁnger dependent Ubiquitin E3
Ligase activity [17] and after transfection of the wild-type
protein we could detect p53 isoforms, which could correspond
to such ubiquitin conjugates (Fig. 2A). Furthermore, a Topors
induced cell cycle arrest requiring still other sequences was
reported recently [16].
The central domain of the Topors protein also stimulated
the sumoylation of endogenous p53 in HeLa cells after
cotransfection with the YFP-tagged SUMO-1 expression con-
struct. In a p53 immunoblot, bands corresponding in size to
YFP-SUMO-1 modiﬁed forms of p53 were observed after
expression of the Topors(437/574) or the Topors(437/555) mu-
tant (Fig. 3A). Both the size and the dependency of these bands
on cotransfection of YFP-SUMO-1 (compare Fig. 3C)
strongly argue that they represent YFP-SUMO-1 modiﬁed
endogenous p53. The appearance of these YFP-SUMO-1
modiﬁed forms of p53 was accompanied by an increase in
endogenous p53 protein levels, whereas in the absence of over-
expressed SUMO-1 protein, the expression of the central To-
pors domain even led to a decrease in p53 levels (Fig. 3C).
In parallel, we examined the inﬂuence of the Topors central
domain on p53 transcriptional activity by reporter gene assays
after additional cotransfection of a luciferase reporter gene
with a synthetic p53 DNA binding site [23]. Transfection of
the central Topors domain led to an enhancement of p53 tran-
scriptional activity in the presence of YFP-SUMO-1 (Fig. 3B),
but not after cotransfection of the YFP protein only (Fig. 3D).
However, the dose dependencies of the Topors-mediated in-
Fig. 1. Topors promotes the accumulation of conjugated forms of YFP-SUMO-1 in vivo. (A, B) HeLa cells were cotransfected with a constant
amount (1 lg) of YFP-SUMO-1 expression construct and increasing amounts of pCATCH-Topors plasmids (0.3, 1, or 3 lg), which express the
indicated parts of the Topors protein with an N 0-terminal Flag-tag epitop under control of the HCMV promoter. In all transfections, total DNA
content was adjusted to 4 lg by the addition of pCATCH vector DNA. Unconjugated monomeric and conjugated high-molecular weight forms of
YFP-SUMO-1 in whole cell extracts were analyzed by immunoblotting with a polyclonal YFP antibody and are indicated by arrows or brackets,
respectively. (C, D) HeLa cells cotransfected with the same concentrations of Flag-tagged Topors expression plasmids as in (A) and (B) and 1 lg of
either a YFP (upper panel) or a YFP-SUMO-1 (lower panel) expression construct were subjected to immunoblot analysis with the anti-Flag
monoclonal antibody M2. (E) Schematic representation of the Topors protein with the N-terminal RING ﬁnger domain, the arginine–serine rich
(RS) and a close-up of the central region required for interaction with SUMO-1 and SUMO-1 modiﬁcation of Topors. The mutants encompassing
diﬀerent parts of this central domain are shown in the lower part of the ﬁgure.
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the Topors-mediated stimulation of p53 transcriptional activ-
ity on the other side diﬀered markedly. Whereas p53protein levels and the concentration of sumolated p53 forms
already reached a maximum at low concentrations of transfec-
ted Topors constructs, p53 activity increased steadily with
Fig. 2. Topors enhances the sumoylation of exogenous p53. (A, B)
HeLa cells were cotransfected with 1 lg of p53 expression plasmid
pRC/CMV-p53, 1 lg of expression constructs for either the YFP
protein or an YFP-SUMO-1 fusion protein, and increasing amounts of
the pCATCH-Topors expression constructs (1 or 3 lg for the wild-type
Topors protein and the RING ﬁnger deletion, and 0.3 or 1 lg for the
various parts of the Topors central domain). Total DNA content was
adjusted to 5 lg with pCATCH vector DNA. Unmodiﬁed and YFP-
SUMO-1 modiﬁed forms of p53 in whole cell extracts were analyzed by
immunoblotting with the monoclonal p53 antibody DO-1 and are
indicated by arrows. Two p53 species with slightly reduced mobility,
which may correspond to ubiquitinated forms of p53, are indicated by
ﬁlled dots. (C) p53-immunoprecipitates of transfections corresponding
to the whole cell extracts shown in (A), lanes 1, 2 and 4 or (B), lane 4,
respectively, were subjected to immunoblot analysis with a polyclonal
anti-YFP antibody. The YFP-SUMO-1 modiﬁed form of p53 is
indicated by an arrow.
Fig. 3. The Topors central domain enhances sumoylation and the
transcriptional activity of endogenous p53 in HeLa cells in the
presence of YFP-SUMO-1. (A–D) HeLa cells were cotransfected with
1 lg of YFP-SUMO-1 (panels A and B) or YFP (panels C and D)
expression constructs and increasing amounts (0.3, 1.0, or 3.0 lg) of
the indicated pCATCH-Topors expression constructs. Total DNA
content was adjusted with pCATCH vector DNA. (A, C) Unmodiﬁed
and YFP-SUMO-1 modiﬁed forms of endogenous p53 in whole cell
extracts were analyzed by immunoblotting with the monoclonal p53
antibody DO-1 and are indicated by arrows. As a loading control
(lower panel), cell extracts were additionally immunoblotted with an
antibody against UBC9, which also shows that Topors has no major
inﬂuence on UBC9 expression levels. (B, D) Cells were additionally
cotransfected with 1 lg of the p53 responsive reporter plasmid P13-
Luc. Luciferase activities were determined 40 h post-transfection,
corrected for the corresponding protein concentration, and normalized
for the values obtained in the absence of cotransfected Topors
proteins. The columns and error bars represent the arithmetic mean
and S.D. from three independent experiments.
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tion, while stabilizing p53 under certain circumstances, may
actually prevent a concomitant increase in its transcriptional
activity. The increase in p53 transcriptional activity at higher
Topors concentrations might be due to the Topors-mediated
sumoylation of other cellular proteins involved in the regula-
tion of p53 transcriptional activity.
To show that Topors can also catalyze the sumoylation of
p53 in vitro, we performed sumoylation assays with puriﬁed
SUMO-1, E1 enzyme SAE1/SAE2, E2 enzyme UBC9, and
in vitro transcribed/translated p53 as a substrate. Upon addi-
tion of puriﬁed wild-type GST-Topors protein, the appearance
of the sumoylated form of p53 was strongly stimulated with a
concomitant decrease in the level of unmodiﬁed p53 (Fig. 4).
In line with the in vivo results, a GST-Topors fusion protein
Fig. 4. Topors promotes the sumoylation of p53 in a reconstituted
system. (A, B) The SUMO-1 modiﬁcation of in vitro transcribed/
translated and 35S-methionine labelled p53 was assayed in the presence
of 2 lg SUMO-1, 100 ng SAE1/SAE2 and 40 ng UBC9 (Assay-Mix).
Where indicated, increasing amounts (0.25, 0.5 and 1.0 lg) of puriﬁed
GST-Topors fusion proteins were added. As a control (lane 2 in both
ﬁgures), 1.0 lg of puriﬁed GST was added. Arrows indicate the
unmodiﬁed form of p53 and p53 modiﬁed by a single SUMO-1 moiety,
respectively. An asterisk indicates a truncated form of p53 generated in
the in vitro transcription/translation reaction and two asterisks mark
the presumed sumolated form of this truncated p53 protein.
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lar increase in p53 sumoylation. We used a GST-Topors fusion
protein with additional amino acids as compared to the
mutants employed for the previous cell culture experiments,
because still shorter GST-Topors proteins exhibited markedly
diﬀerent solubility properties (data not shown), suggesting an
improper folding of these rather small Topors domains in
the context of the GST fusion protein. After addition of
Topors we observed additional p53 bands, whose migration
behaviour suggested that they represented p53 molecules con-
jugated with several SUMO-1 moieties as recently described by
others [24]. Thus in contrast to the Mdm2 protein, which can
enhance p53 sumoylation dependent on ARF-mediated target-
ing of p53 to the nucleolus, but exhibits no sumoylation
activity in a cell-free system [25], Topors directly enhances
sumoylation of p53. In summary, Topors meets all the criteria
that were originally deﬁned for E3 ligases in the largely analo-
gous ubiquitination pathway. It (i) binds to both the SUMO-1
E2 conjugating enzyme UBC9 and SUMO-1 itself as demon-
strated previously [15]; (ii) Topors binds to p53, the substrate
of the modiﬁcation reaction [13,22]; and (iii) Topors stimulates
the modiﬁcation of p53 in vivo and in a reconstituted in vitro
system.Acknowledgement: This work was supported by a grant from the Deut-
sche Forschungsgemeinschaft (SFB 506).References
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